Market PenetrationShield Therapeutics's interim results confirmed the continued strong growth of its iron deficiency treatment Accrufer as it continues to penetrate the significant oral iron replacement therapy market in the US.
Prescription CoverageThe percentage of non-covered prescriptions dropped from 37% to 22%, contributing to the revenue growth.
Revenue GrowthShield expects to deliver $32.2m of revenues for 2024, driven primarily by US Accrufer sales which grew 153%.